| Literature DB >> 16247440 |
Carl Nathan1, Frederick M Goldberg.
Abstract
Economists, a biomedical researcher and a business executive have formulated three contrasting proposals to address the shortfall in antibiotic R&D. Their proposals, which emphasize advance purchase contracts, not-for-profit research, and tax incentives, respectively, share some features with provisions in bills pending before the US Congress that could potentially reshape the R&D landscape for this essential class of drugs.Entities:
Mesh：
Substances：
Year: 2005 PMID： 16247440 DOI： 10.1038/nrd1878
Source DB: PubMed Journal: Nat Rev Drug Discov ISSN： 1474-1776 Impact factor: 84.694